Commenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “In 2018, we continued to drive growth in many of our products. I am particularly pleased with the important regulatory approvals for our new fibrinogen concentrate, fibryga®, which received regulatory approval in Switzerland, our new 10% IVIG product, panzyga®, approved for the US market, and our new SCIG product, cutaquig®, which was approved by both Health Canada and the FDA. These approvals are significant achievements for the company and, most importantly, bring substantial benefits to patients as well as physicians. Based on our strong product portfolio we are well positioned for the future.”
Over the last seven years, the Octapharma Group has accomplished a remarkable compound annual growth rate of 14% and for 2018 reports sales of €1.797 billion – €77 million (4.5%) more than 2017’s figure (on a constant currency basis, the growth rate is 6.6%).
Gross profit in 2018 was €631 million, which is €39 million higher than achieved in 2017. Operating income was €346 million. The total operating expenses were €285 million. Significant investments were made for our future prosperity - €87 million for the R&D efforts and €153 million into the extension of the production capacity and infrastructure. The investments in research and infrastructure strongly position the company to fulfil the future needs of healthcare professionals and the increasing number of patients around the world.
In the last 12 months, several important milestones were reached in the expansion of the plasma and recombinant product portfolio. To ensure each liter of plasma is used to best effect, the company will continue to expand its product portfolio with innovative new products and services, and enter new markets.
Major projects within Program 2019, the development initiative launched in 2014 to increase our production capacity and overall efficiency of manufacturing operations, were completed and contributed to the company’s growth. The investments in talent, equipment and property prepare the company for the demands of the future.
“2018 was a year of strong execution at Octapharma,” said Roger Mächler, Chief Financial Officer of the company. “Our significant investments in research and infrastructure strongly position our company to fulfil the needs of more healthcare professionals and patients around the world.”
The Annual Report 2018 provides a comprehensive overview of the Octapharma Group, including our corporate governance and the financial results. To download the full Octapharma 2018 Annual Report visit www.annualreport.octapharma.com.
The vision of Octapharma is: “Our passion drives us to provide new health solutions advancing human life”. Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood. Our company values are Ownership, Integrity, Leadership, Sustainability and Entrepreneurship.
In 2018, the Group achieved €1.8 billion in revenue, an operating income of €346 million and invested €240 million into R&D and in capital expenditures in order to ensure future prosperity. Octapharma employs 8,314 people worldwide to support the treatment of patients in 115 countries with products across three therapeutic areas:
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden.